Hearing the words "stomach cancer" can feel like the ground disappears beneath you. Fear, confusion, and a flood of questions – with no time to waste. What happens next? What are the treatment options? Is there hope for recovery? This guide is here to give you clarity in the chaos. We’ve gathered clear, reliable, and up-to-date information to walk you through each step – from diagnosis to treatment planning – so you can move forward with confidence and a sense of control.
Understanding Stomach Cancer: Key Facts and Current Challenges
Stomach cancer, or gastric cancer, arises from the inner lining of the stomach and progresses through several stages if left untreated. The vast majority of cases - over 90% - are adenocarcinomas, which develop from glandular cells responsible for producing stomach acid and digestive enzymes. While the overall incidence has declined in parts of Europe, stomach cancer remains a leading cause of cancer-related deaths globally, especially due to late-stage diagnosis.
The European Cancer Information System (ECIS) [1] states that over 130,000 new cases were diagnosed in Europe in 2022. Although the number of individuals who survive at the advanced stages is low, this suggests the necessity to detect the disease at an earlier stage and elaborate on more effective treatment plans.
Booking Health's mission is to find the best medical solution tailored specifically to your situation - especially when standard treatments have failed or local medical options have been exhausted.
We combine the expertise of leading medical institutions, evidence-based medicine, and a thorough analysis of your medical history to offer not just "another try," but a well-informed next step.
Gastric cancer often begins with chronic inflammation, most commonly caused by long-term infection with Helicobacter pylori (H. pylori) – a bacterium classified as a Group 1 carcinogen by NCCN guidelines [2]. Over time, this inflammation can lead to cellular changes known as intestinal metaplasia, which may progress to dysplasia and eventually invasive cancer.
Other contributing factors include genetic predispositions, a diet high in preserved or smoked foods, tobacco use, and certain inherited syndromes, such as hereditary diffuse gastric cancer (HDGC).
Classification and Staging of Stomach Cancer
Precise staging is the key to treatment planning. The TNM classification system is the standard way of evaluating tumor spread, which has been aligned with the guidelines of the European Society for Medical Oncology (ESMO) and the Union for International Cancer Control (UICC) [3] in Europe. It uses results of imaging (CT, PET-CT, endoscopic ultrasound) and, in case of necessity, diagnostic laparoscopy.
STAGE 1Tumor is in the inner layers of the stomach wall, without the involvement of lymph nodes. The prognosis is usually good, provided that they are treated early enough.
STAGE 2Further infiltration into the muscular layer or early lymph node metastasis. Frequently, multimodal treatment is needed.
STAGE 3Local and regional spread, which refers to invasion of numerous lymph nodes or surrounding structures. Surgery can be an option, although it usually comes after chemotherapy.
STAGE 4Distant metastases (liver, peritoneum, lungs). At this point, the treatment is palliative and aims to manage the symptoms and prolong life.
Two patients can share an identical stage and still respond to treatment in completely different ways — because staging alone never tells the whole story. Molecular profile, overall health, prior treatment history: these variables reshape the clinical picture entirely. What looks uniform on paper rarely is. The person behind the diagnosis matters.
This is why individualized assessment isn't optional. Booking Health medical experts are available for consultation within 24 hours and they don't recommend anything before conducting an in-depth analysis of each patient's individual case.
Nothing is assumed. Everything is reviewed.
Standard Treatment Options For Stomach Cancer
The decisions made on the treatment of gastric cancer largely depend on the stage of the tumor, the site, the histological type, the molecular features, and the general health condition of the patient. The ESMO Clinical Practice Guidelines (2022) [4] explain that a multidisciplinary approach is necessary to guarantee the optimal possible outcome that incorporates the contributions of oncology, surgery, radiology, pathology, and nutrition support.
Surgery For Stomach Cancer: The Cornerstone for Curative Intent
Surgical resection forms the best curative therapy for patients with localized or locally advanced tumors (stage I-III). The surgery for stomach cancer is determined by the location and size of the tumor:
Tumor is in the inner layers of the stomach wall, without the involvement of lymph nodes. The prognosis is usually good, provided that they are treated early enough.
Further infiltration into the muscular layer or early lymph node metastasis. Frequently, multimodal treatment is needed.
Local and regional spread, which refers to invasion of numerous lymph nodes or surrounding structures. Surgery can be an option, although it usually comes after chemotherapy.
Minimally invasive surgery of the stomach (laparoscopic or robotic) is becoming more common, especially in the case of an early-stage disease, with no notable difference in oncologic outcomes and reduced recovery time.
For patients considering surgery abroad, access to high-volume surgical centers - where gastric resections are performed regularly rather than occasionally - is one of the most clinically significant factors in outcome. Surgeons who operate on stomach cancer every week develop a precision and familiarity with anatomical variation that simply cannot be replicated in lower-volume settings.
When Booking Health selects a clinic for a patient, treatment outcome statistics for the specific procedure are part of the evaluation criteria, not just the hospital's general reputation.
Perioperative and Adjuvant Chemotherapy For Stomach Cancer
Perioperative chemotherapy is the most frequent treatment in patients with resectable stage II and III stomach cancer. It is prescribed in the European oncology guidelines, such as the European Society for Medical Oncology (ESMO). This is a combination of chemotherapy administered prior to surgery (neoadjuvant) to reduce the size of the tumor and subsequent chemotherapy (adjuvant) to lower the chance of recidivism.
Now desirable regimen in Europe is a combination of four drugs that have been found to be more successful than the older three-drug regimens. The rationale of this strategy lies in the solid evidence of large clinical trials that revealed an increased survival and complete tumor removal.
The treatment of gastric cancer is usually managed in various cycles before surgery and also after the recovery, and is very appropriate to treat those patients who are in good general health and are capable of undergoing a rigorous treatment regimen.
Targeted Therapy For Stomach Cancer: When It May Be Used
In some advanced stomach cancer cases, the tumors can also have certain molecular features that open up to targeted forms of treatment. Amplification or overexpression of a specific growth factor receptor, which is related to the growth of tumor cells, is one of the most clinically relevant markers.
In patients with tumors that are positive for this marker, it has been established that added to regular chemotherapy, a targeted agent can enhance the overall survival. This is currently a first-line treatment option in this kind of molecular subtype according to the European Society of Medical Oncology (ESMO) recommendations.
It is highly recommended that this biomarker be tested prior to administering the treatment for systemic gastric cancer in advanced disease because it is useful in determining the appropriate therapeutic strategy, and the patient is also assured of the best and personalized treatment they can get.
Before committing to any treatment plan - have you had full molecular profiling done? If not, this step matters more than most patients realise.
Comprehensive biomarker panels can reveal options that standard diagnostics miss entirely. Some travellers abroad use the initial evaluation strategically: not just to confirm a diagnosis, but to challenge it - and sometimes, to change it.
A fresh, evidence-based second opinion has uncovered treatment paths that were previously invisible. That's not a rare outcome. It happens. Booking Health arranges comprehensive diagnostic evaluations for gastric cancer - covering expert multidisciplinary review from start to finish.
Over the past few years, there have been other treatment options for gastric cancer as compared to conventional ones. Several novel therapeutic options are currently employed in clinical practice throughout Europe as an effective way of treating metastatic, recurrent, and peritoneal forms of the disease. These approaches have already shown clinical effectiveness, high safety levels, and increasing prevalence in the world, providing patients with new opportunities when the old approaches might have become exhausted.
Dendritic Cell-Based Immunotherapy For Stomach Cancer: Immune Activation with Proven Scientific Foundation
Dendritic cell therapy is an approved form of active immunotherapy in the treatment of gastric cancer that assists the immunity to in identifying and targeting the cancerous cells. Dendritic cell therapy is a procedure based on isolating dendritic cells from the blood of the patient and, under controlled laboratory conditions, pulsing them with antigens associated with tumors. The antigens are digested and presented on the surface of the dendritic cells.
When ready, the antigen-loaded dendritic cells are returned to the patient, usually through a simple injection. They move to regional lymph nodes where they engage naive T-lymphocytes, thereby triggering a cytotoxic T-cell attack against tumor cells bearing the same antigens.
The scientific basis of this approach was created by Dr. Ralph Steinman, whose discovery of dendritic cells won him the 2011 Nobel Prize in Physiology or Medicine. His work has brought radical changes to modern medicine in the context of immune regulation and anti-cancer defense.
Dendritic cell therapy is already in use in certified European clinics in the case of gastric cancer, demonstrating:
Enhanced tumor-specific immunity
Late recurrence of surgical and systemic treatment
Good tolerability and possibility to use in weakened patients
The approach is highly productive when it is applied as part of a holistic treatment regimen used to avoid the development of the disease.
To gain a deeper understanding of dendritic cell therapy, its mechanisms, and its clinical applications in gastric cancer, we invite you to watch an in-depth interview with Professor Frank Gansauge, a pioneer in the field. In this discussion, he explains how dendritic cells train the immune system to recognize and destroy cancer cells, shares insights from his extensive clinical experience, and highlights the future potential of this innovative immunotherapy.
VIDEO
Prof. Frank Gansauge: How Dendritic Cell Therapy is Transforming Modern Cancer Treatment
TACE (Transarterial Chemoembolization) For Stomach Cancer: Localized Control for Liver Metastases and Innovative Neoadjuvant Therapy
Transarterial chemoembolization (TACE) is an image-guided, minimally invasive method of administering localized chemotherapy to the liver metastases through a combination of arterial embolization and delivery of localized chemotherapy. The operation is done by injection of chemotherapy drugs selectively into the branches of the hepatic artery serving the tumor, and the embolic material is then injected to stop the flow of blood. These two mechanisms enable the chemotherapeutic agents to be in contact with the tumor for a long time and, at the same time, deprive the tumor of oxygen and nutrients.
TACE has shown great usefulness in gastric cancer that has metastatic spread in the liver. In contrast to systemic chemotherapy, TACE enables high local drug levels at low systemic exposure, which reduces toxicity and enhances tolerability even in patients with comorbidities and poor performance status.
In clinical practice in European oncology centers, TACE has shown:
Reduction in the size of the tumor to an average of 70%, and local control of disease in up to 70% of cases
Normal liver enzymes, which denote functional liver recovery
Better overall survival, particularly when incorporated in multimodal treatment regimes, which may also involve systemic chemotherapy, immunotherapy, or ablation
Due to the positive safety profile and the quantifiable results, TACE has become one of the standard treatment methods in patients with unresectable liver metastases of gastric cancer. It is beneficial when the patient is not eligible to receive surgical resection or the patient needs to have a reduced tumor burden before systemic therapy.
The effectiveness of using TACE as a neoadjuvant therapy in gastric cancer is confirmed by a recent multicenter clinical study that was published in the Journal of Clinical Oncology (2023) [5]. Among 43 patients, 42 (97.7%) had a successful D2 resection after TACE. Postoperative pathological analysis showed tumor regression in most cases.
Tumor Response Grade After TACE in Gastric Cancer
Short-Term Complications After TACE
Recurrence Patterns After TACE
3-Year Survival Outcomes After TAC
*Outcomes of transarterial chemoembolization in neoadjuvant therapy of patients with gastric cancer [5]
Based upon these results, TACE is currently being established as a standard therapy in the multidisciplinary therapy for gastric cancer, especially in patients with liver metastases or in those who need a reduction in the tumor burden before proceeding with systemic therapy.
Regional Chemotherapy in Gastric Cancer
Regional chemotherapy for stomach cancer transforms how drugs reach tumors – delivering concentrated doses directly, through arterial catheters, rather than diluting them across the entire circulatory system.
The technique employs three primary methods: hypoxic abdominal stop-flow perfusion, upper abdominal perfusion, and intraarterial infusion. Each isolates specific anatomical regions, flooding tumor tissue with chemotherapy concentrations 15-20 times higher than systemic administration achieves. Sophisticated filtration removes residual drugs from circulation within 45 minutes.
a Scheme of UAP-F technique. b Stop-flow balloon catheter [6]
Clinical outcomes validate this approach. A multicenter study of 38 patients with peritoneal metastatic gastric cancer who had failed systemic chemotherapy demonstrated median overall survival of 17.4 months – extending to 23.5 months in patients who had undergone prior tumor resection [6].
No Grade 3 or 4 toxicity occurred across 114 treatment cycles. Patients tolerate the procedure exceptionally well – a stark contrast to conventional chemotherapy's debilitating effects. This precision targeting matters enormously for gastric cancer with peritoneal spread that represents one of the most challenging clinical scenarios.
Electrochemotherapy for Stomach Cancer
Electrochemotherapy against gastric cancer (GaCa) uses controlled electrical pulses to alter permeability of malignant cells. The mechanism is elegant: brief electrical fields create temporary nanopores in tumor cell membranes which allows chemotherapy molecules to flood inside rapidly.
The procedure positions specialized needle electrodes 2.5-3 centimeters apart around tumor margins. Computer-controlled generators then deliver precisely calibrated pulses synchronized with cardiac rhythm (to prevent arrhythmia). After electro-chemotherapy opens these cellular pathways, drugs penetrate 70-80% more effectively than standard administration. Gastric tumors – particularly those with peritoneal involvement or located near vital structures – respond to treatment well. When combined with regional perfusion techniques, this approach achieves tumor shrinkage rates exceeding 60%, even in cases resistant to chemotherapy.
Financial considerations vary. Many patients weigh electrochemotherapy cost against the advantages it offers. The cost of electrochemotherapy includes imaging guidance, anesthesia, and the multidisciplinary team work.
EXPERT
Professor Karl Reinhard Aigner
Oncology, Regional Chemotherapy, Oncological Surgery
Professor Karl Reinhard Aigner pioneered combining arterial perfusion with electrooration, he performed over 20,000 procedures throughout his career.
HIPEC (Hyperthermic Intraperitoneal Chemotherapy) For Stomach Cancer: Strength in Surgical Precision
HIPEC is a modern and high-tech surgical procedure that is employed in the management of gastric cancer peritoneal invasion. Having removed tumor deposits that can be seen, using cytoreductive surgery, heated chemotherapy is placed into the abdominal cavity to destroy any microscopic disease left behind.
Results of investigations demonstrate:
Overall survival is more than 20 months in properly selected patients
Lower levels of peritoneal recurrence
Positive long-term results
HIPEC is now a regularly used procedure in most European oncologic centers and part of a few national guidelines on the treatment of advanced gastric cancer with peritoneal metastasis.
Patient selection for HIPEC requires careful evaluation – outcomes are strongly influenced by the extent of peritoneal involvement and the completeness of cytoreduction achieved.
Centers with substantial HIPEC experience have well-developed selection criteria, and seeking care from a team that performs this procedure regularly is clinically important. This is one of the factors Booking Health reviews when recommending a center to patients with peritoneal disease.
PIPAC achieves chemotherapy through pressurized aerosol delivery into the peritoneal cavity through laparoscopy. This increases tissue penetration and drug distribution.
It has shown:
Have a response rate of more than 60 percent in patients with peritoneal metastases
Even when patients had advanced, treatment-resistant disease, median overall survival was 12-15 months
Outstanding tolerability, repeated treatment without admission
PIPAC is currently used in dozens of oncology hospitals throughout Europe in peritoneal carcinomatosis, including that of gastric origin.
Stomach Cancer Treatment Abroad
For a large number of patients with stomach cancer, going to foreign countries to get cancer treatment provides access to superior treatment modalities, multidisciplinary care, and knowledge that these patients lack in their own countries. Such a decision can be driven by the confluence of the medical needs and the wish to explore the most effective treatment options available.
Patients prefer international care in order to obtain access to novel treatments, including HIPEC, PIPAC, dendritic cell immunotherapy, and TACE – those measures that are becoming more and more common in international cancer guidelines.
International cancer centers are usually high-volume centers that have a team of professionals who specifically treat gastric cancer. They usually have shorter waiting times for diagnostic imaging, surgery, and new treatment options.
Among the most sought-after destinations is Germany. There is a widespread belief that cancer treatment in Germany is expensive. In reality therapy in German oncology centers is often more affordable than in many other developed countries (including the United States). This applies equally to advanced gastric cancer (even at stage IV). Below are indicative treatment-related costs:
Radical gastrectomy followed by intestinal reconstructionStarts from:24.021,00 €
Cytoreductive surgery combined with HIPECStarts from:51.875,00 €
Comprehensive diagnostic evaluation for gastric cancerStarts from:3.970,00 €
Comprehensive diagnostic evaluation for gastric cancerStarts from:3.970,00 €
These costs reflect not only the procedures themselves but also the level of medical excellence patients receive, including:
Precision-based diagnostic protocols
Access to state-of-the-art oncological therapies
Treatment by internationally recognized specialists
Minimally invasive and organ-preserving surgical techniques
As a result – German clinics for stomach cancer offer a balanced combination of clinical quality and financial transparency. Final treatment costs are calculated on an individual basis taking into account the patient’s condition, disease stage and the selected therapeutic strategy.
Making a decision to receive treatment in a foreign country may provide a greater range of treatment options, second opinion opportunities, and an opportunity to obtain personal care in the highest-quality facilities. To a great number of patients with advanced, or treatment-resistant gastric cancer, it is not merely an alternative – it is the possibility of living longer and living better.
Logistics can break a patient before treatment ever begins. Translating medical records, making appointments, thinking about visa requirements, language barriers – each task demands expertise that most families simply don't have. And they manage all of this while facing a serious illness.
This is where Booking Health steps in. With over 20 years in international oncology and ISO 9001 quality certification, they absorb the entire coordination burden – so patients don't have to. Documentation, translations, travel arrangements, hotel bookings, airport transfers, interpreter support: every detail handled. Every single one.
Traditional vs. Innovative Approaches for Stomach Cancer Treatment
Based on clinical data from Booking Health.
Characteristic
Standard Methods
Innovative Methods
2-Year Survival Rate
~30% for advanced-stage cases
~55-65% in selected patients receiving multimodal therapies
Response Rate
Approx. 15%
50-70% (depending on method and tumor profile)
Treatment Duration
6-8 cycles over 4-6 months
Typically 3-5 sessions (e.g., PIPAC, TACE, dendritic immunotherapy)
Adverse Effects
High (nausea, immunosuppression, fatigue, hair loss)
Generally mild (localized pain, low systemic toxicity)
Medical Procedures Costs for Stomach Cancer
Based on pricing insights from Booking Health. Final treatment costs may vary depending on individual clinical factors, length of hospital stay, required post-treatment supervision, and additional services such as diagnostics, travel assistance, and accommodation logistics.
Treatment Method
GERMANY*
Great Britain
USA
Standard Treatment
€80,000 - €150,000 full course
€90,000 - €165,000 full course
€100,000 - €180,000 full course
Innovative Methods
€25,000 - €60,000 full course
€70,000 - €120,000 full course
€100,000 - €150,000 full course
Stomach Cancer Treatment Clinics in Germany
The search for reliable information about foreign hospitals for stomach cancer treatment is often accompanied by an excess of data and contradictory sources (which complicates the choice). To simplify this process, it is worth noting that German medical centers are considered the strongest in the oncology field.
German hospitals rank first among the countries of the European Union in terms of total expenditures in the field of oncology. The high level of medical technologies in Germany (which underlie both fundamental scientific research and its effective implementation in clinical practice) deserves special attention.
Leading German Hospitals for Stomach Cancer
Hospital
Oncology Expertise
Innovative Opportunities
University Hospital Duesseldorf
University cancer center with extensive clinical experience
Access to advanced regional and immunotherapy methods based on individual indications
LMU Munich
Leading academic hospital with international recognition
Opportunity to implement innovative protocols and participate in clinical trials
University Hospital Ulm
Specialization in complex and advanced cancer cases
Modern local and systemic tumor control technologies
University Hospital Frankfurt
Leading interventional oncology center
Minimally invasive methods and regional oncology technologies
University Hospital Duesseldorf
University Hospital Duesseldorf is a modern stomach cancer treatment center, that combines academic medicine and innovative oncological technologies. The clinic specializes in complex forms of the disease (including stage IV). HIPEC and PIPAC are actively used here for peritoneal metastases (as well as regional chemotherapy and TACE to control tumor growth). Immunotherapeutic approaches, including dendritic cells, are integrated into the holistic treatment for stomach cancer. Highly accurate diagnostics, multidisciplinary consultations and individual stomach cancer therapy make the clinic a strong candidate for the title of best hospital for stomach cancer in Europe.
University Hospital of Ludwig Maximilian University of Munich
University Hospital LMU Munich is considered one of the best stomach cancer hospitals in the world (due to its deep scientific base and access to clinical research). This stomach cancer clinic offers a full range of treatment options – from radical surgery to interventional oncology. Patients can benefit from electrochemotherapy, regional chemotherapy, TACE and innovative immunotherapy protocols. HIPEC and PIPAC are used in accordance with international guidelines. The combined approach allows for the best stomach cancer treatment in the world – even in complex clinical cases.
University Hospital Ulm
University Hospital Ulm is known for its systemic approach to cancer treatment and is one of the leading clinics for stomach cancer in Germany. The clinic specializes in combined stomach cancer therapy regimens (combining surgery with regional chemotherapy, electrochemotherapy and modern methods of local tumor control). Particular attention is paid to patients with metastatic forms where HIPEC and PIPAC are used. The multidisciplinary approach ensures holistic treatment for stomach cancer taking into account the patient's general condition and prognosis.
University Hospital Frankfurt am Main
University Hospital Frankfurt am Main is a highly specialized stomach cancer treatment center with a powerful department of interventional oncology. TACE, regional chemotherapy and electrochemotherapy are actively used here to treat inoperable and recurrent tumors. Immunotherapy with dendritic cells is integrated into personalized protocols. Due to this, the institution is often considered the best hospital for stomach cancer among patients looking for innovative solutions.
From Uncertainty to Action with Stomach Cancer: Dan’s Path with Booking Health
At the time when Dan Mitcalfe started to seek a way of treating stomach cancer overseas, he had to cope with the challenge of arranging medical services in a foreign country. This has brought him to the University Hospital Frankfurt am Main in Germany. Dan tells us that Booking Health assisted in making the treatment program at the University Hospital Frankfurt am Main in Germany. The planning of care abroad is a daunting process, particularly when it has to work within a tight schedule, health records, and overseas laws. However, with the right guidance, Dan could have concentrated on what was most important – receive the treatment he required.
He attributes the professionalism and responsiveness of the Booking Health team: "I would like to compliment all staff members of the company, Brother Muhammad, and Sister Nour in particular, on the level of their professionalism and timeliness in all visa processes and their assistance."
His experience shows the need for a trusted partner in coordinating matters in the event of medical care abroad, as was the case with Dan. Booking Health made the process easy and hassle-free by taking care of the visa arrangements to maintaining constant communication.
A Medical Journey: Every Step of the Way With Booking Health
Finding the right treatment strategy is rarely straightforward — especially for patients who have already been through multiple rounds of treatment, consulted different specialists, and received conflicting recommendations. The weight of all that information, combined with the urgency that a cancer diagnosis imposes, can make it genuinely difficult to step back and evaluate options clearly.
What tends to help most is having access to an independent, medically informed review of your case — one that is not tied to a single institution’s capabilities or one physician’s specialty. Booking Health has been working in international oncology for over 20 years, supporting patients from the United States, Canada, Europe, and Australia — most of whom had already consulted leading specialists in their home countries before reaching out.
The goal is not to find “just another attempt,” but to identify the optimal treatment strategy: the right method, the right clinic, and the physician with the most relevant experience for the specific situation.
After your initial inquiry — free and without obligation — a medical expert (not a Call Center Operator) is available within 24 hours.
WHAT YOU RECEIVE IMMEDIATELY INCLUDES:
A detailed review of your medical history, including an in-depth analysis of previous treatments and their outcomes
Identification of real medical options when standard protocols have been exhausted
A recommendation for a specific doctor and clinic, supported by treatment outcome statistics
Once care begins, a personal medical case manager — a qualified physician — oversees your case and remains in contact for up to 12 months. This person does not disappear after the booking is confirmed. They monitor the treatment process, protect your interests if anything does not go according to plan, and are there throughout every stage.
THE PRACTICAL SUPPORT IS COMPREHENSIVE:
Full handling of medical documentation and translations
Clinic appointments, treatment scheduling, flights, hotels, transfers, and interpreters - all organized
Transparent treatment budget with no hidden costs - you know the full cost in advance
Complication insurance up to €200,000, covering potential medical costs if complications arise after treatment
Decision-making support when several treatment options are available, with clear explanation of benefits and risks
Frequently Asked Questions of Our Patients About Stomach Cancer Answered
What is the best treatment for stomach cancer?
The treatment of stomach cancer should be the most effective based on its stage and the unique features of the patient's condition. The possible treatment includes surgery, chemotherapy, targeted therapy, or new approaches such as HIPEC, PIPAC, or dendritic cell-based immunotherapy. Individual care plans established in the major oncology facilities lead to the most favorable outcomes.
Is stomach cancer curable?
The cancer in the stomach is treatable, particularly when it is at the initial stages. Curative therapy tends to include surgical and chemotherapy or other measures. Advanced gastric cancer cases can also be treated with chemoembolization or dendritic cell immunotherapy.
What are the symptoms of stomach cancer?
The typical symptoms are pain in the abdomen, indigestion, weight loss, nausea, early satiety, and tiredness. In case the symptoms are persistent, to achieve effective treatment of cancer, it is important to be diagnosed at an early stage.
Can I get treated for stomach cancer abroad?
True, a number of patients prefer to undergo treatment outside their countries to receive more advanced treatments that are not easily accessible in their home countries. German clinics also provide new treatment options for stomach cancer that include dendritic cell therapy, chemoembolization.
Is immunotherapy effective for stomach cancer?
Some cases of immunotherapy for gastric cancer with the use of dendritic cells are also promising. It may be used either independently or in conjunction with other treatments. It is a personalized method, which raises the immune response of the body and makes it more effective in killing cancer cells.
What hospitals offer stomach cancer surgery in Europe?
Major European hospitals are the ones that focus on the surgery of stomach cancer and overall care. The centers frequently combine new treatment methods such as HIPEC or PIPAC during or after surgery, and this gives international patients access to top-notch cancer care.
What is the survival rate for stomach cancer?
The survival rate is based on the stage at which it is diagnosed and the treatment used. Stomach cancer at its initial stages has a higher survival rate than at its advanced stages. Optimal results can be achieved even in metastatic cases by the use of innovative approaches like chemoembolization, PIPAC, and dendritic cell therapy.
What are the main treatment options for stomach cancer?
Treatment for stomach cancer depends on the stage and may include surgery, chemotherapy, and targeted therapy. In particular, advanced cases can benefit from innovative methods (e.g., HIPEC, PIPAC, TACE, and dendritic cell immunotherapy), which improve outcomes and are available in leading European oncology centers.
How much does stomach cancer treatment cost in different countries?
The cost of stomach cancer treatment can vary widely. For example, in Germany, standard treatment costs €80,000-€150,000, while innovative methods (e.g., HIPEC or dendritic cell therapy) range from €25,000-€60,000. Prices are higher in the UK (€90,000-€165,000) and USA (€100,000-€180,000). In contrast, Australia offers limited access to these innovative treatments, and when available, costs may be 3-4 times higher than in Europe.
What is the 2-year survival rate for stomach cancer?
For advanced-stage stomach cancer, the 2-year survival rate is approximately 30% with standard treatments. However, it rises to 55-65% in patients receiving multimodal innovative therapies (e.g., HIPEC, PIPAC, or dendritic cell immunotherapy).
What is the treatment response rate for stomach cancer?
The response rate for stomach cancer treatment averages 15% with conventional methods, compared to 50-70% with innovative therapies customized to the tumor profile (including targeted or immunotherapeutic approaches).
How long does stomach cancer treatment usually last?
Standard stomach cancer treatment involves 6-8 chemotherapy cycles over 4-6 months. In contrast, innovative procedures (e.g., TACE, PIPAC, or dendritic cell therapy) may require only 3-5 sessions.
What are the common adverse effects of stomach cancer treatment?
Conventional treatments for stomach cancer often cause nausea, fatigue, immune suppression, and hair loss. On the other hand, innovative therapies (e.g., PIPAC, HIPEC, and TACE) are generally well tolerated. They can cause only mild, localized side effects with minimal systemic toxicity.
Authors
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova and Dr. Bohdan Mykhalniuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
05.Journal of Clinical Oncology. Outcomes of transarterial chemoembolization in neoadjuvant therapy of patients with gastric cancer: A multicenter retrospective cohort study.https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.410
06.Aigner K, Vashist YK, Selak E, Gailhofer S, Aigner KR. Efficacy of Regional Chemotherapy Approach in Peritoneal Metastatic Gastric Cancer. J Clin Med. 2021;10(23):5322.[DOI]
Start Treatment in 48 Hours — Fixed Price
100 000+ patients advised in 10 years
Save 40–70 % on total cost
Personal coordinator 24/7 in your language
Free, no commitment. Reply within 24 h.
Same Clinic Price — Many More Benefits with Booking Health
benefit
direct clinic booking
With Booking Health
Clinic list price
same clinic price
same clinic price
Fixed, all‑inclusive estimate (no hidden fees)
Total savings on travel & logistics (≈ 40 – 70 %)
Start of treatment within 48 hours
10 + years medical‑tourism expertise
Medical case review by a dedicated medical board
Personal coordinator 24/7 in your language
Visa, flights, transfer and accommodation support
Certified translations & document handling
Access to innovative methods in Germany
Pre‑negotiated fixed pricing with top clinics
Risk of unexpected extra costs
fixed price
Contact Us
Booking Health guarantees
Analysis of statistics and selection of the best clinic
Fixed final price (additional costs will be covered by insurance)
One year of medical support by your attending physician after the treatment
thanks for your request.
Within 1 working day, a medical advisor will study your request and contact you by phone (German or your local number will be displayed).
